Research on weight loss drugs like Ozempic shows varied results for mental health impacts, with some patients experiencing ...

New research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in ...

Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was ...

Could the same medication that causes people to lose weight hold the key to reducing drinking? In a new paper at the European ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Medications like semaglutide and liraglutide may help to reduce the risk of heart attacks, strokes, and other major adverse ...

First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...

People taking semaglutide or liraglutide reduced their alcohol consumption by two-thirds within four months, according to ...

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with obesity and ...

Giving obese children weight-loss jabs is effective and helps prevent battles around mealtimes, researchers say. Experts at the European Congress on Obesity in Malaga, Spain, presented findings ...

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European ...

Oral semaglutide demonstrated superior cardiometabolic outcomes relative to placebo and active comparators, including empaglifozin, in T2D.